Media

Press Release

2013

Nuron Biotech to Present at BIO Business Forum® – April 22, 2013
Nuron Biotech Selected to Present at Future Leaders in the Biotech Industry Conference – April 02, 2013
Nuron Biotech Receives Pennsylvania Bio’s 2013 Deal of the Year Award for Advancing Bioscience Industry – March 18, 2013

2012

Nuron Biotech Raises $80 Million from HealthCare Royalty Partners – December 20, 2012
Nuron Biotech Acquires Commercial, Preventive Vaccine Meningitec™ from Pfizer – December 10, 2012
Nuron Biotech Completes Enrollment of a Pivotal Phase 3 Study for Proprietary Recombinant Human Interferon Beta-1b (NU100) in Relapsing Remitting Multiple Sclerosis – November 13, 2012
Nuron Biotech Expands Portfolio with Exclusive, Worldwide License for an Amyloid Beta 42 DNA Vaccine Candidate for Alzheimer’s Disease – April 9, 2012
Nuron Biotech Expands Portfolio with License of Therapeutic and Prophylactic Hepatitis Vaccine Candidates – March 5, 2012
Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market – Jan. 13, 2012

2011

Nuron Biotech Initiates Phase 3 Study of Proprietary Recombinant Human Interferon beta-1b in Relapsing Remitting Multiple Sclerosis – Nov 1, 2011
Nuron Biotech to Develop Long-acting Version of Proprietary Recombinant Human Interferon Beta-1b Utilizing TheraPEGPegylation Technology – May 26, 2011
Nuron Acquires Assets Related to HibTITER® Conjugate Vaccine from Wyeth (a wholly owned subsidiary of Pfizer) – Apr 6, 2011
Nuron Biotech Selects the Merck BioManufacturing Network as Manufacturing Supplier for Next Generation Interferon Beta Pivotal Study for Multiple Sclerosis – Feb 10, 2011

In the News

2013

Nuron Biotech CEO Dr. Shankar Musunuri interviewed on Executive Leaders Radio – January 11, 2013

2012

Nuron Biotech VP Regulatory Affairs, Dr. Vijay Tammara received “Regulatory Science Achievement Award” at AAPS Annual Meeting and Exposition – October 14, 2012
Nuron Biotech CEO Dr. Shankar Musunuri interviewed with CEO IntroNet – March 22, 2012
Nuron Biotech CEO Dr. Shankar Musunuri participated in discussion with CEO IntroNet, “Leaving a large corporation to start a new business” – March 22, 2012
Nuron Biotech CEO Dr. Shankar Musunuri featured in UConn Today – March 12, 2012
Nuron Biotech Inks Vaccine License with Mitsubishi Tanabe featured in BioWorld® Today- January 13, 2012

2011

Nuron Biotech CEO Dr. Shankar Musunuri Interviews with the Executive Leaders Radio – August 26, 2011
Nuron Biotech Selects the Merck BioManufacturing Network as Manufacturing Supplier for Next Generation Interferon Beta Pivotal Study for Multiple Sclerosis – Feb 10, 2011
Catalent Announces Partnership with Nuron Biotech to Provide Sterile Delivery and Supply of MS Treatment in Phase 3 Clinical Study – January 31, 2011

2010

BaroFold Licenses BaroFeron to Nuron Biotech – May 17, 2010